Substantial Depletion of Vicine, Levodopa, and Tyramine in a Fava Bean Protein-Based Nutritional Product.
INTERNATIONAL JOURNAL OF FOOD SCIENCE 2021;
2021:6669544. [PMID:
33564674 PMCID:
PMC7867441 DOI:
10.1155/2021/6669544]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Revised: 01/01/2021] [Accepted: 01/16/2021] [Indexed: 11/18/2022]
Abstract
A commercial fava bean protein isolate and a liquid nutritional product formulated with it were tested by validated HPLC methods for the favism-associated pyrimidine glycoside vicine, the dopamine precursor levodopa, and the biogenic amine tyramine. The vicine, levodopa, and tyramine concentrations in the protein isolate-306, 13.3, and <0.5 mg/kg, respectively-when expressed on a protein basis-34, 1.5, and <0.06 mg/100 g protein, respectively-were at least 96% lower than the vicine, levodopa, and tyramine (protein-based) concentrations reported for fava beans (≥900, ~200, and ~4 mg/100 g protein, respectively). This was also true for the vicine (13 mg/kg or 22 mg/100 g protein), levodopa (≤0.17 mg/kg or ≤0.3 mg/100 g protein), and tyramine (0.08 mg/kg or 0.14 mg/100 g protein) concentrations in the nutritional product. On the basis of these data, one serving (11 fl. oz.) of the nutritional product would deliver approximately 5 mg of vicine, <1 mg of levodopa, and <0.1 mg of tyramine.
Collapse